Slate of Candidates for BIO Emerging Companies Section Governing Board 2013-2014 Term

  1. Brian Atwood, Managing Director, Versant Ventures
  2. Robert Beall, President & CEO, Cystic Fibrosis Foundation
  3. Marc Beer, Chief Executive Officer, Aegerion Pharmaceuticals, Inc
  4. Alexis Borisy, Chairman, Foundation Medicine
  5. Ron Cohen, President & CEO, Acorda Therapeutics, Inc
  6. John Crowley, Chairman & CEO, Amicus Therapeutics, Inc
  7. Douglas Doerfler, President & CEO, MaxCyte, Inc
  8. Glen Giovannetti, Global Biotechnology Leader, Ernst & Young, LLP
  9. Maxine Gowen, President & CEO, Trevena, Inc
  10. Faheem Hasnain, President & CEO, Receptos, Inc
  11. Paul Hastings, President & CEO, OncoMed Pharmaceuticals, Inc
  12. Jeffrey Hatfield, President & CEO, Vitae Pharmaceuticals, Inc
  13. Russell Herndon, President & CEO, Hydra Biosciences, Inc
  14. Daniel Junius, President & CEO, ImmunoGen, Inc
  15. Perry Karsen, Chief Operations Officer, Celgene Corporation
  16. Rachel King, President & CEO, GlycoMimetics, Inc
  17. Robert Kiss, Managing Director/Portfolio Manager, JP Morgan Asset Management
  18. Scott Koenig, President & CEO, MacroGenics, Inc
  19. Barbara Kosacz, Partner, Cooley, LLP
  20. Emer Leahy, President & CEO, PsychoGenics, Inc
  21. Jonathan Leff, Partner, Deerfield
  22. Nick Leschly, chief bluebird, bluebird bio
  23. John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals, Inc
  24. Edward Mathers, Partner, New Enterprise Associates
  25. Thomas Mathers, Chief Executive Officer, CoLucid Pharmaceuticals, Inc
  26. Gordon McCauley, President & CEO, Allon Therapeutics, Inc
  27. Russell Medford, President & CEO, Salutria Pharmaceuticals, LLC
  28. John Mendlein, Chairman & CEO, aTyr Pharma
  29. Steven Mento, Co-Founder, President, Chairman & CEO, Conatus Pharmaceuticals, Inc
  30. Kenneth Moch, President & CEO, Chimerix, Inc
  31. Arlene Morris, Chief Executive Officer, Syndax Pharmaceuticals, Inc
  32. Mike Naraci, Chief Executive Officer, OrexigenTherapeutics, Inc
  33. John Orwin, Chief Executive Officer, Affymax, Inc
  34. Jeffrey Ostrove, President & CEO, Ceregene, Inc
  35. Stuart Peltz, President & CEO, PTC Therapeutics, Inc
  36. Adelene Perkins, President & CEO, Infinity Pharmaceuticals, Inc
  37. Kristine Peterson, Chief Executive Officer, Valeritas, Inc
  38. Mark Pruzanski, Founder, President & CEO, Intercept Pharmaceuticals, Inc
  39. Timothy Rodell, President & CEO, GlobeImmune, Inc
  40. Arthur Sands, President & CEO, Lexicon Pharmaceuticals, Inc
  41. David Schenkein, Chief Executive Officer, Agios Pharmaceuticals, Inc
  42. Moncef Slaoui, Chairman, Research & Development, GlaxoSmithKline, plc
  43. Gil Van Bokkelen, Chairman & CEO, Athersys, Inc
  44. Harold Van Wart, President, Director & CEO, Metabolex, Inc
  45. Timothy Walbert, President, Chairman & CEO, Horizon Pharma, Inc
  46. Kleanthis Xanthopoulos, President & CEO, Regulus Therapeutics, Inc
  47. Bradford Zakes, Chief Executive Officer, Cerevast Therapeutics, Inc
  • Stephen Sherwin, Chair Emeritus(Non-Voting Member)